Metabolic syndrome and cerebrovascular disorders

Cover Page

Cite item

Full Text


A combination of a number of risk factors, known as metabolic syndrome (MS), leads to fast progression of vascular diseases and the development of severe complications. Earlier we showed that abnormalities of the system of hemorheology and hemostasis accompanying MS played a significant role in the development of ischemic stroke. In this report we present three clinical cases of combination of MS with various forms of ischemic cerebrovascular pathology, including description of a patient who underwent surgical treatment because of a severe stenotic process in brachiocephal arteries. Shown is the effect of MS on different pathogenic constituents of vascular disorders, including the system of hemorheology and hemostasis. The necessity for complex therapy of main manifestations of MS in acute and chronic cerebrovascular disorders is grounded.

About the authors

Marine M. Tanashyan

Research Center of Neurology

ORCID iD: 0000-0002-5883-8119

D. Sci. (Med.), Prof., Corresponding member of RAS, Deputy Director for science, Head, 1st Neurological department

Russian Federation, Moscow

S. V. Orlov

Research Center of Neurology

Author for correspondence.
Russian Federation, Moscow

Roman B. Medvedev

Research Center of Neurology

ORCID iD: 0000-0003-3887-0418

Cand. Sci. (Med.), researcher, 1st Neurological department, Institute of Clinical and Preventive Neurology

Russian Federation, Moscow

Olga V. Lagoda

Research Center of Neurology

ORCID iD: 0000-0001-7562-4991

Cand. Sci. (Med.), senior researcher, 1st Neurological department, Institute of Clinical and Preventive Neurology

Russian Federation, Moscow

N. G. Omelchenko

Research Center of Neurology


N. A. Glotova

Research Center of Neurology



  1. Орлов С.В. Гемореология и гемостаз у больных с ишемическими инсультами на фоне метаболического синдрома. Дисс. … канд. мед. наук. М., 2006.
  2. Талызин П.А., Затейщиков Д.А. Блокада эндоканнабиноидных рецепторов – новый подход к лечению основных факторов риска атеросклероза. Фарматека 2006; 8; 10–15.
  3. Танашян М.М., Орлов С.В., Домашенко М.А. и др. Метаболический синдром и ишемический инсульт. Анн. клин. эксперим. неврол. 2007; 3: 3–11.
  4. Чазова И.Е., Мычка В.Б. Метаболический синдром и артериальная гипертония. Consilium medicum 2002; 11; 587–590.
  5. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. JAMA 2001; 285: 2486–2497.
  6. Golgstein L.B., Adams R., Alberts M.J. et al. Primary prevention of Ischemic Stroke: guideline from the American Heart Association. Circulation 2006; 113: e873–e923.
  7. Haffner S.M., Ferranini E., Hazuda H.P. et al. Clustering of cardiovascular risk factors in confirmed prehypertensive individuals. Hypertension 1992; 20: 38–45.
  8. Henefeld M., Leonhardt W. Das metabolische Syndrome. Deutsch Ges. Wes. 1980; 36: 545–551.
  9. Rodriguez-Colon M.S., Jingping Mo, Yinkang Duan et al. Metabolic syndrome clusters and the risk of incident stroke. Stroke 2009; 40: 200–205.
  10. Reaven G.M. Banting Lecture 1988. Role of insulin resistance inhuman disease. Diabetes 1988; 37: 1595–1607.

Supplementary files

Supplementary Files

Copyright (c) 2009 Tanashyan M.M., Orlov S.V., Medvedev R.B., Lagoda O.V., Omelchenko N.G., Glotova N.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-83204 от 12.05.2022.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies